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With the progress of targeted therapies in 
advanced melanoma and the need for bet-
ter adjuvant drugs, many are now asking 
whether precision treatment could be used 
at an earlier stage of melanoma diagnosis 
in the adjuvant setting, which accounts 
for the majority of melanoma diagnoses. 
Indeed, a number of adjuvant clinical trials 
using targeted therapies for the treatment 
of stage IIC and stage III melanomas have 
now been initiated.
Several targeted monotherapies and 
combination therapies are currently being 
evaluated for melanoma  treatment in the 
adjuvant setting in both stage IIC and 
stage III melanomas (clinical trials NCT-
01667419, NCT01682083, NCT00553618, 
NCT01782508, and NCT01682213). How-
ever, because the risk of recurrence is less than 
100% for these patients, multiple patients 
would need to be treated for every one patient 
who would receive benefit from the adjuvant 
therapy (9). Prognostic biomarkers are there-
fore needed to predict melanoma recurrence, 
but to date good prognostic biomarkers that 
accurately predict the outcome of stage IIB-C 
or stage III melanomas are lacking.
Prognostic markers determine the risk 
of tumor recurrence as a result of growth 
of cancerous cells that have escaped surgical 
resection, most likely due to metastasis, and 
as such these cancer cells are undetectable 
at the time of diagnosis. Indeed, initial pres-
entation of recurrence was local in 10.9%, 
in transit in 9.9%, involving a regional 
lymph node in 34.4%, and at a distant 
site in 44.9% of patients with metastasis 
(9). Several studies have demonstrated the 
presence of BRAF mutations as a marker of 
poor prognosis in both the metastatic and 
locally advanced settings. This is impor-
tant because targeted therapy could help 
to eliminate metastasized cells that harbor 
the BRAF mutation.
Targeted therapy has revolutionized 
 treatment for advanced melanoma. Clinical 
trials have demonstrated unprecedented 
survival benefits in advanced melanoma 
patients treated with Vemurafenib (1, 2). 
Vemurafenib is a targeted inhibitor that 
specifically binds to mutant BRAF pro-
teins containing V600E or V600K amino 
acid substitutions, preventing constitutive 
activation of the mitogen-activated protein 
kinase (MAPK) pathway, and resulting in 
antitumor effects of inhibition of cell pro-
liferation and apoptosis induction (3).
New treatments are evolving rapidly 
in this area. The FDA has approved two 
other monotherapeutic drugs, Dabrafenib 
and Trametinib, which are also inhibitors 
of growth stimulatory effects of mutant 
BRAF, or its downstream effector pathways, 
and these have proven to improve survival 
rates (4, 5). Moreover, clinical trials are 
demonstrating further prolonged survival 
in addition to reduced treatment related 
toxic side-effects through combinatorial 
use of several of these targeted drugs (6). 
However, there is a great downside to tar-
geted therapy in advanced melanoma: in 
practically all cases, drug resistance inevita-
bly develops, and patient death inexorably 
follows (2, 6).
Stage IIB-C and stage III melanomas 
have a lower disease burden than stage IV 
melanoma, and yet these melanomas are 
at a significant risk of tumor recurrence 
following surgical resection (7). Currently 
there is a high demand for new and effective 
adjuvant treatments to mitigate the risk of 
recurrence, and there are a number of adju-
vant therapies under investigation for stage 
IIB-C and stage III patients. The only FDA-
approved adjuvant drugs for melanoma are 
interferon-alpha and pegylated interferon, 
which marginally improve overall survival 
(OS) for high-risk recurrent tumors (8). 
BRAF mutation predicts shorter OS in 
stage IV melanoma (10), which is consist-
ent with clinical outcomes of tumor regres-
sion upon Vemurafenib administration in 
advanced melanoma patients; inhibition 
of a marker that is directly associated with 
poor prognosis results in prolonged sur-
vival. In stage III resected tumors BRAF 
mutations are associated with a signifi-
cantly shorter DFS and OS (11, 12), and 
they have been shown to promote metas-
tasis through mechanistic studies, albeit 
presumably associated with the progres-
sion and growth of the metastatic disease 
rather than the initiation of metastasis 
(13). Thus, for BRAF mutation-positive 
stage III patients, adjuvant targeted ther-
apy may be of benefit. In contrast, BRAF 
mutation does not appear to have sig-
nificant impact on prognosis in stage I 
or stage II melanomas. Numerous studies 
have shown the BRAF mutation does not 
affect the Disease Free Interval (DFI) or 
OS after surgical resection of melanomas 
at these stages (14–16), and thus it does 
not influence tumor recurrence.
In deciding whether to use a targeted 
treatment for melanoma in the adjuvant 
setting, either for stage III or stage IIB-C, 
it is important to consider whether the 
tumor cells that avoid surgical resection, 
presumably due to early metastasis, would 
continue to harbor the mutation being tar-
geted (e.g., BRAF). This can be guided by 
the observations that most primary mela-
nomas with a BRAF mutation have paired 
secondary lesions also harboring the muta-
tion (17). This may be explained by the fact 
that BRAF mutations are acquired during 
the early stages of tumor progression, for 
example during radial to vertical growth 
phase (18), resulting in a larger portion 
of the primary tumor with the mutation. 
Clones that acquire metastatic capability 
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will most likely therefore possess the BRAF 
mutation and so BRAF mutant targeted 
therapy should work.
As BRAF mutations influence tumor 
growth, it is unlikely that they would confer 
metastatic capability. For instance, primary 
tumors with a BRAF V600E mutation may 
frequently be paired with secondary lesions 
without the mutation (17, 19). Colombino 
and colleagues found 6 of 44 BRAF mutant 
primary melanoma patients whose pri-
mary melanomas were positive for the 
BRAF V600E mutation, yet had a BRAF 
wild-type secondary lesion (17). To explain 
this, Yancovitz and colleagues showed intra-
tumoral heterogeneity of clones with respect 
to BRAF V600E mutation status, and con-
cluded BRAF mutations were not necessary 
for metastasis (19). Importantly, administra-
tion of targeted therapy inhibiting mutant 
BRAF to BRAF wild-type patients has been 
shown not only to have absence of benefit, 
but can also cause a growth advantage in 
those tumor cells by paradoxically stimulat-
ing the MAPK pathway (20).
In addition, BRAF wild-type primary 
tumors may be paired with mutant BRAF 
secondary tumors, due to the acquisition of 
the BRAF mutation at the secondary site. 
These patients would be likely to benefit 
from adjuvant targeted therapy, with the 
degree of benefit depending on how early 
the BRAF mutation had occurred during the 
cellular evolution of the secondary tumor. 
Mutant BRAF might therefore be a useful 
therapeutic target in the metastatic lesions of 
stage III melanoma patients for this reason, 
as compared to those patients with a local-
ized melanoma of stage IIB-C. Mann et al. 
(12) for example, have shown that BRAF 
mutation status may also be combined with 
an expression signature to enhance the abil-
ity to predict melanoma recurrence.
Although it might be questioned whether 
patients with stage IIB melanoma should 
also be included in the adjuvant therapy 
clinical trials, despite the promising leads 
mentioned above there is currently not a 
lot of prognostic information that supports 
the use of mutant BRAF targeted therapy to 
treat stage III melanomas in the adjuvant 
setting, and even less information to support 
the use of BRAF targeted therapy to treat 
stage IIB-C melanomas. While randomized 
phase III clinical trials are currently recruit-
ing to evaluate the use of BRAF targeted 
therapy for stage IIC and III melanomas 
in the  adjuvant setting as an alternative to 
 interferon drugs, these treatments are not 
without the potential to develop some or all 
of the adverse side-effects of the BRAF tar-
geted therapies (2). In addition, BRAF muta-
tions activate the MAPK pathway, which is 
associated with increased MITF expression 
(21). Therefore inhibiting BRAF activity in 
stage II melanomas could lead to repression 
of both MITF and miR-211 expression in 
those tumors (see He et al., submitted), and 
if the environmental signals are conducive, 
then this could subsequently cause up-
regulated expression of BRN2, a factor that 
is thought to be associated with phenotype 
switching (22), and so induce metastasis.
Based on the points we have outlined 
above, it is our opinion that treatment of 
stage II melanoma with BRAF inhibitors in 
the absence of data from suitable prognos-
tic biomarkers that adequately predict the 
outcome of stage II melanomas, could lead 
to adverse outcomes for these patients. It is 
hoped that these trials will provide insight 
as to how targeted therapies perform in 
the adjuvant setting in patients with tumor 
recurrence. The identification of which 
patients have a high-risk of recurrence 
of melanoma requires better biomarkers 
of tumor progression and prognosis. In 
addition, new biomarkers of melanoma 
metastasis are needed, together with the 
concurrent development of new or exist-
ing drugs for use in the adjuvant setting.
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